VEGFA and neoplasm: This hepatoprotective effect may be attributed to donafenib’s improved molecular stability and enhanced safety profile compared to sorafenib, as demonstrated in the ZGDH3 trial (lower incidence of drug-related adverse events: 85.3% vs. 95.5%) (12).Donafenib, as a new type of multitarget TKI, exerts inhibitory effects on the VEGF and PDGF pathways, which can block tumor angiogenesis and growth and improve the embolization effect of TACE (31).